Adherence to treatment of osteoporosis: A need for study

Osteoporosis International

Volumn 18, Issue 10, 2007, Pages 1311-1317

  Lekkerkerker, F ^a   Kanis, J A ^b   Alsayed, N ^c   Bouvenot, G ^d   Burlet, N ^e   Cahall, D ^f   Chines, A ^g   Delmas, P ^h   Dreiser, R L ⁱ   Ethgen, D ^j   Hughes, N ^k   Kaufman, J M ^l   Korte, S ^m   Kreutz, G ⁿ   Laslop, A ^o   Mitlak, B ^p   Rabenda, V ^q   Rizzoli, R ^r   Santora, A ^s   Schimmer, R ^t   Tsouderos, Y ^u   Viethel, P ^v   Reginster, J Y ^w,x   more..

^a MEDICINES EVALUATION BOARD   (Netherlands)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c Supreme SA   (Belgium)

^d Ancien Délégué Général de la Fédération de l'Hospitalisation Privée   (France)

^e International Osteoporosis Foundation Switzerland   (Switzerland)

^f SANOFI   (France)

^g PFIZER INC   (United States)

^h EDOUARD HERRIOT HOSPITAL   (France)

ⁱ BICHAT HOSPITAL   (France)

^j GLAXOSMITHKLINE   (United States)

^k AMGEN INC   (United States)

^l GHENT UNIVERSITY HOSPITAL   (Belgium)

^m NOVARTIS PHARMA AG   (Switzerland)

ⁿ Council for International Organisations of Medical Sciences ^*  (Switzerland)

^o Austrian Medicines and Medical Devices Agency   (Austria)

^p ELI LILLY AND COMPANY   (United States)

^q UNIVERSITY OF LIÈGE   (Belgium)

^r WORLD HEALTH ORGANIZATION   (Switzerland)

^s MERCK RESEARCH LABORATORIES   (United States)

^t F HOFFMANN LA ROCHE LTD   (Switzerland)

^u INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^v MERCK THERAMEX   (Monaco)

^w UNIVERSITY OF LIÈGE   (Belgium)

^x Policliniques L BRULL Quai Godefroid Kurth   (Belgium)

more..

Author keywords

Adherence; Compliance; Persistence; Registration; Reimbursement

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; FRACTURE; HUMAN; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE;

BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SELF ADMINISTRATION;

EID: 34548587917     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0410-4     Document Type: Review

References (49)

1. Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 15:1003-1008
2. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-928
3. Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rtes in osteoporotic women: relationship to vertebral and non-vertebral fractures from 2 US claims databases. Mayo Clinic Proc 81:1013-1022
4. Clowes JA, Peel NFA, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomised controlled trial. J Clin Endocrinol Metab 89:1117-1123
5. Yood RA, Emani S, Reid JI et al (2003) Compliance with pharmacological therapy for osteoporosis. Osteoporosis Int 14:965-968
6. Silverman S, Siris E, Abbott T et al (2003) Adherence to bisphosphonate therapy is associated with decreased non-vertebral osteoporotic fracture risk. J Bone Miner Res 20 (suppl 1):S286
7. Weycker D, Macarios D, Edelsberg J et al (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis Int 17:1645-1652
8. Compston JE, Seeman E (2006) Compliance with osteoporosis therapy is the weakest link. Lancet 368:2005-2006
9. Miller NH (1997) Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102:43-49
10. Willey C, Redding C, Stafford J et al (2000) Stages of change for adherence with medication regimens for chronic diseases: development and validation of a measure. Clin Ther 22:858-871
11. Donovan JL (1995) Patient decision making. The missing ingredient in compliance research. Int J Technol Assess Health Care 11:443-455
12. Kyngas H, Duffy ME, Kroll T (2000) Conceptual analysis of compliance. J Clin Nurs 9:5-12
13. Lutfey KE, Wishner WJ (1999) Beyond "compliance" is "adherence". Improving the prospect of diabetes care. Diabetes Care 22:635-639
14. Henneman EA, Lee JL, Cohen JI (1995) Collaboration: a concept analysis. J Adv Nurs 21:103-109
15. Madden BP (1990) The hybrid model for concept development: its value for the study of therapeutic alliance. ANS Adv Nurs Sci 12:75-87
16. Mullen PD (1997) Compliance becomes concordance. B Med J 314:691-692
17. McCombs JS, Thiebaudet P, McLaughlin-Milet C et al (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271-287
18. Cooper A, Drake J, Brankin E, on behalf of the persist investigators (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once weekly alendronate: results from the PERSIST study. J Clin Practice 60:896-905
19. Cramer JA, Amonkar MM, Hebborn A et al (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453-1460
20. Fardellone P, Gaudin AF, Cotte FE (2005) Comparison of the persistence of daily and weekly bisphosphonates in female patients treated for osteoporosis. J Bone Miner Res 20 (Suppl 1):S285-S286
21. Solomon DH, Avorn J, Katz et al (2005) Compliance with osteoporosis indications. Arch Intern Med 165:2414-2419
22. Docherty SM, Goodley A, Steel SA (2005) Compliance and effect of bone protective treatment in elderly females: 5 year follow-up study. Rheumatology 44(Suppl 1):134
23. Tosteson ANA, Grove MR, Hammond CS et al (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209-216
24. Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporosis Int 14:259-262
25. Prowse D, McGetrick V, Thompson AJ et al (2005) Persistence with oral therapy is high amongst patients followed in a DGH osteoporosis. Clinical Rheumatology 44(Suppl):135
26. Briesacher BA, Andrade S, Kahler K et al (2006) Economic impact of the previous year's adherence with bisphosphonates. J Bone Miner Res 21(suppl 1):S171
27. World Health Organization (2003) Adherence to long-term therapies: Evidence for action. WHO, Geneva, Switzerland
28. Lamberg L (2000) Patient-physician relationship critical even during brief "medication checks". JAMA 284:29-31
29. Eraker SA, Kirscht JP, Becker MH (1984) Understanding and improving patient compliance. Ann Intern Med 100:258-268
30. Ammassari A, Trotta MP, Murri R et al (2002) Study group correlates and predictors of adherence to highly active antiretroviral therapy: Overview of Published. JAIDS 31(suppl 3):S123-S127
31. McCloskey E, de Takats D, Orgee J et al (2005) Characteristics associated with non-persistence during daily therapy. Experience from the placebo wing of a community-based clinical trial. J Bone Miner Res 20(suppl 1):S282
32. Claxton AJ, Cranmer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296-1310
33. Thompson P, Cooper C, Carr A (2005) Factors influencing adherence to bisphosphonates for osteoporosis. J Bone Miner Res 20 (suppl):S394
34. Irvine J, Baker B, Smith J et al (1999) Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study Psychosom Med 61:566-575
35. Granger BB, Swedberg K, Ekman I, for the CHARM investigators (2005) Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 366:2005-2011
36. Delmas PD, Vrijens B, Eastell R et al (2007) Improving measurements of persistence on actonel treatment (IMPACT) investigators. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:296-304
37. Cramer JA, Silverman S (2006) Persistence with Bisphosphonate Treatment for Osteoporosis: Finding the root of the problem. Am J Med 119:S12-S17
38. Kanis JA et al (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11:1-256
39. Stevenson M, Davies S (2006) DSU economic evaluation of pooled alendronate and risedronate compared with strontium ranelate, raloxifene, etidronate and teriparatide http://guidance.nice.org.uk/page.aspx?o=370643)
40. Spilker B (1991) Methods of assessing and improving patient compliance in clinical trials. In: Cramer JA, Spilker B (eds) (1991) Patient compliance in medical practice and clinical trials. Raven press, New York pp 37-56
41. Melnikow J, Kiefe C (1994) Patient compliance and medical research. Issues in methodology. J Gen Int Med 9:96-105
42. Turbi C, Herrero-Beaumont G, Acebes JC et al (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clin Ther 26:245-256
43. Farmer KC (1999) Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 21:1074-1090
44. Straka RJ, Fish JT, Benson SR et al (1997) Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy 17:126-132
45. Lee JY, Kusek JW, Greene PG et al (1996) Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens 9:719-725
46. Mason BJ, Matsuyama JR, Jue SG (1995) Assessment of sulfonylurea adherence and metabolic control. Diabetes Educ 21:52-57
47. Paes AH, Bakker A, Soe-Agnie CJ (1998) Measurement of patient compliance. Pharm World Sci 20:73-77
48. Pullar T, Feely M (1990) Problems of compliance with drug treatment: new solutions? Pharm J 245:213-215
49. Schwed A, Fallab CL, Burnier M et al (1999) Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. J Clin Pharmacol 39:402-409